High prevalence of CDH23 mutations in patients with congenital high-frequency sporadic or recessively inherited hearing loss

Abstract

Background

Mutations in CDH23 are responsible for Usher syndrome 1D and recessive non-syndromic hearing loss. In this study, we revealed the prevalence of CDH23 mutations among patients with specific clinical characteristics.

Methods

After excluding patients with GJB2 mutations and mitochondrial m.1555A > G and m.3243A > G mutations, subjects for CDH23 mutation analysis were selected according to the following criteria: 1) Sporadic or recessively inherited hearing loss 2) bilateral non-syndromic congenital hearing loss, 3) no cochlear malformation, 4) a poorer hearing level at high frequencies than at low frequencies, and 5) severe or profound hearing loss at higher frequencies.

Results

Seventy-two subjects were selected from 621 consecutive probands who did not have environmental causes for their hearing loss. After direct sequencing, 13 of the 72 probands (18.1%) had homozygous or compound heterozygous CDH23 mutations. In total, we identified 16 CDH23 mutations, including five novel mutations. The 16 mutations included 12 missense, two frameshift, and two splice-site mutations.

Conclusions

These results revealed that CDH23 mutations are highly prevalent in patients with congenital high-frequency sporadic or recessively inherited hearing loss and that the mutation spectrum was diverse, indicating that patients with these clinical features merit genetic analysis.

Electronic supplementary material

The online version of this article (doi:10.1186/s13023-015-0276-z) contains supplementary material, which is available to authorized users.

Background

CDH23, located on chromosome 10, contains 70 exons and encodes a predicted 3354 amino acid protein. The untranslated region is followed by 27 extracellular cadherin repeat domains (exons 2–64), a single-pass transmembrane domain (exon 65), and a cytoplasmic domain (exons 66–70). Among the 113 human cadherin superfamily members, CDH23 is one of 11 that are solely responsible for hereditary diseases [1]. CDH23 is expressed in the outer and inner hair cells. The stereociliary expression of CDH23 in inner ear hair cells exhibits two patterns. One is transient expression during the development of hair bundles with procadherin 15 (PCDH15) and CDH23 forming side links and kinociliary links at their N-termini [2]. The second pattern is stable expression in tip links at the top of stereocilia from the developmental stage onwards until ear maturation. CDH23 homodimers interact in trans with PCDH15 homodimers to form filaments, and they play a key role in the mechanoelectrical transduction channel at the top of the lower stereocilia [3-5].

Mutations in CDH23 are responsible for both Usher syndrome 1D (USH1D: OMIM #601067) [6-9] and autosomal recessive non-syndromic hearing loss (DFNB12: OMIM #601386) [10-12]. Individuals with USH1D usually carry a truncated CDH23 protein because of nonsense, frameshift, or splice-site mutations, whereas those with DFNB12 usually carry missense mutations in any domain [7,10,13]. The mutation spectrums differ regionally, with the Japanese population having a unique mutation spectrum [12,14]. Recently, it was reported that 3.7% of recessive inherited hearing loss cases in the Japanese population involve homozygous or heterozygous CDH23 mutations [12].

In this study, we analyzed CDH23 in a Japanese population that was selected on the basis of DFNB12 and USH1D clinical features [12,14-16] after excluding patients with GJB2 mutations and mitochondrial m.1555A > G and m.3243A > G mutations. We identified an extremely high prevalence of CDH23 mutations in this population, and our findings expanded the CDH23 mutation spectrum, including five novel mutations.

Methods

All participating subjects, or their parents if the subjects were less than 20 years old, provided informed consent. The project was approved by the institutional review board of each institute. The patients were collected from the 11 institutes listed below: National Tokyo Medical Center, Chiba Children’s Hospital, National Mie Hospital, National Center for Child Health and Development, Hyogo Prefectural Kobe Children’s Hospital, Keio University School of Medicine, National Hospital Organization Kanazawa Medical Center, Kanagawa Children’s Medical Center, National Hospital Organization Sendai Medical Center, Kanto Rosai Hospital, and Hiroshima Prefectural Hospital. All investigations were conducted according to the principles expressed in the Declaration of Helsinki.

For the analysis of CDH23 mutations, we selected subjects who did not have hearing loss owing to environmental causes and who had participated in a genetic study at our institutes, with each subject meeting the following criteria: 1) sporadic or recessively inherited hearing loss; 2) bilateral non-syndromic congenital hearing loss; 3) a lack of cochlear malformations among those who underwent a computed tomography scan and/or magnetic resonance imaging; 4) a poorer hearing level at high frequencies (e.g., 2 kHz, 4 kHz) than at low frequencies (e.g., 250 kHz, 500 Hz); and 5) severe or profound hearing loss over 70 dB at frequencies exceeding 2 kHz. These clinical features were based on the reported phenotypes of DFNB12 and USH1D [12,14-16]. Before patient selection for CDH23 mutation analysis, genetic analyses for GJB2 and mitochondrial m.1555A > G and m.3243A > G mutations were conducted in all patients, according to published methods [17,18]. Among 621 probands who participated in a genetic study at our institutes from November 2008 to June 2012 (the first subject group), 72 subjects were selected for CDH23 mutation analysis based on these criteria.

For CDH23 analysis, DNA was extracted from peripheral blood using standard procedures. We PCR-amplified all CDH23 exons using the primers listed in Additional file 1: Table S1. The PCR products were purified and subjected to sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA). SeqScape 2.6 software (Applied Biosystems) was used to analyze data against an NCBI human primary reference sequence (GRCh37.p13). Before SeqScape 2.6 analysis, all known CDH23 mutations within 69 coding regions and flanking 10-bp sequences of transcript variant 1 archived in the BIOBASE HGMD database (last visited on October 2014; BIOBASE, MA, USA) were entered into the SeqScape project files to enable detection of novel variants. Descriptions of DNA and amino acid positions in the literature [6-10,12,14,19] and the HGMD database were reassigned through original test programs to present the information in a consistent format. Prediction of the effect of missense variants on CDH23 protein function was performed using Polymorphism Phenotyping [PolyPhen2 [20] and Protein Variation Effect Analyzer (PROVEAN v1.1.3.) [21].

Frameshift (splice site within ± 2) and nonsense mutations were categorized as pathogenic. The pathogenicity of splice site alterations larger than ± 2 was predicted by NNSPLICE 0.9 version [22]. Novel missense variants were defined as pathogenic if they were 1) non-synonymous; 2) exhibited a low carrier rate (<1%) in 96 normal in-house control Japanese subjects and in public databases [(dbSNP135 [23], 1000GENOME [24], and NHLBI Exome Variant Server [25]]; 3) exhibited high amino acid conservation among 12 primate, 45 mammal, and 43 vertebrate species using UCSC Conservation [26]; 4) demonstrated consistency with phenotypes in family members; and 5) were detected in patients with hearing loss identified as heterozygous in association with another previously reported or determined heterozygous mutation. Variants who failed to meet criteria 1–4 were defined as non-pathogenic. Those who met criteria 1–4 but failed to fulfill criterion 5 were considered to have uncertain pathogenicity. For the purpose of this study, frameshift, splice site, and nonsense mutations were categorized as “truncating” mutations, and missense and in-frame insertion or deletion mutations were considered “non-truncating” mutations.

In addition, we further examined CDH23 mutations retrospectively in subjects who participated in a genetic study at our institutes from April 2001 to October 2008 (the second subject group). For this analysis, we selected subjects who had obvious progressive hearing loss as determined by repeated audiometry, profound hearing loss over 80 dB at frequencies above 2 kHz, as well as fulfilling the five aforementioned criteria for the first subject group. For these subjects, we additionally performed Sanger sequencing for CDH23 mutations.

Results

In the first subject group, we analyzed a total of 621 probands, and 492 underwent clinical selection for CDH23 gene testing after excluding individuals with GJB2 mutations and mitochondrial deafness. Figure 1 presents the study procedure together with the selection process for the primary screening. Using this procedure, 72 subjects were selected for CDH23 mutation analysis (14.6% of the selected individuals). Homozygous or compound heterozygous CDH23 mutations were identified in 13 subjects (18.1% of tested subjects), and nine subjects had heterozygous mutations (12.5% of tested subjects).

Figure 1.

Flow chart of the selection and exclusion processes and the number of subjects at each point.

In the second subject group, 546 probands participated in the genetic study. After retrospective selection using the more stringent criteria, 15 subjects were selected. After direct sequencing for CDH23 mutations, three subjects were identified with homozygous or compound heterozygous pathogenic CDH23 mutations (20.0% of tested subjects), and three subjects were shown to have heterozygous mutations (20.0% of tested subjects).

A total of 16 pathogenic CDH23 mutations were found in 56 subjects from 28 families. Homozygous or compound heterozygous pathogenic mutations were found in 21 subjects, which included 16 probands. Heterozygous mutations were found in 12 probands. CDH23 mutations included 11 previously reported mutations [p.P240L, p.P346S, p.E956K, p.D1626A, p.Q1716P, p.R2029W, p.R1417W, p.E2438K, p.L2473P, p.R2489H, and c.6712 + 1G > A [7,12,14,27], as well as four novel mutations (Table 1). Twelve of the mutations were missense, one was a frameshift and three were splice-site mutations. Fifteen variants were considered to have uncertain pathogenicity (Table 1). These include five variants previously reported as uncertain [12,14,28,29], as well as 10 novel variants. We also found 49 non-pathogenic CDH23 variants, including 12 new variants (Additional file 2: Table S2). All the variants reported in this study were registered in the LOVD-CDH23 database [30].

Table 1.

Possible pathologic and uncertain variants found in this study

Number in probands (in 346 allele)
Types of variants	Location	Amino acid change	Nucleotide change	Genomic position(Chr10)	Domain	Evolutionary conservation*	Homozygote	Compound heterozygote	Heterozygote	Allele frequency in normal controls	Allele frequency in ESP6500	dbSNP135	PolyPhen2 score	PROVEAN score	Novel or Known	Reference
Missense	Exon 7	p.P240L	c.719C > T	73330641	EC3	11/11, 44/44, 40/40	4	7	6	0/192	0	rs121908354	0.999	−3.051	Known	[12]
	Exon 11	p.P346S	c.1036C > T	73377052	-	12/12, 42/42, 41/41	0	1	0	0/192	0	None	0.989	−5.768	Known	[27]
	Exon 16	p.G539D	c.1616G > A	73437314	EC5	12/12, 43/43, 42/42	0	1	0	0/190	0	None	0.092	−4.272	Novel
	Exon 18	p.D645G	c.1934A > G	73442277	EC6	12/12, 45/45, 42/42	0	1	0	0/192	0	None	1.000	−5.596	Novel
	Exon 25	p.E956K	c.2866G > A	73464800	EC9	12/12, 45/45, 42/42	0	4	0	0/192	0	None	0.999	−2.939	Known	[14]
	Exon 35	p.R1417W	c.4249C > T	73498294	EC13	12/12, 32/44, 0/40	0	0	1	0/192	0	None	0.453	−1.346	Known	[12]
	Exon 39	p.D1626A	c.4877A > C	73537468	EC15	12/12, 45/45, 41/42	0	1	0	0/192	0	None	0.952	−5.3	Known	[14]
	Exon 39	p.Q1716P	c.5147A > C	73538025	EC16	12/12, 45/45, 40/41	0	2	0	0/192	0	None	0.972	−2.68	Known	[12]
	Exon 46	p.R2029W	c.6085C > T	73550924	EC19	12/12, 45/45, 39/40	0	2	2	0/192	0	None	0.999	−4.659	Known	[12]
	Exon 52	p.E2438K	c.7312G > A	73559336	EC23	12/12, 43/44, 15/41	0	2	0	0/192	0	None	0.314	−0.383	Known	[14]
	Exon 53	p.L2473P	c.7418 T > C	73560448	EC23	11/11, 45/45, 36/36	0	0	1	0/192	0	None	0.998	−5.603	Known	[12]
	Exon 53	p.R2489H	c.7466G > A	73560496	EC23	12/12, 45/45, 36/36	0	0	1	0/192	0	rs141986620	0.459	−1.219	Known	[12]
Frameshift	Exon 48	p.L2223Wfs	c.6667del C	73553352	-	-	0	1	0	0/192	0	None	-	-	Novel
	Exon 63	p.N3044Tfs	c.9129 del G	73571123	-	-	0	1	0	0/190	0	None	-	-	Novel
Putative spice site	IVS11	-	c.1135-1G > T	73403617	-	12/12, 41/41, 4/4	0	0	1	0/192	0	None	-	-	Novel
	IVS48	-	c.6712 + 1G > A	73553398	-	712/12, 44/44, 41/41	0	1	0	0/192	0	None	-	-	Known	[11]
Uncertain pathogenicity variants
Missense	Exon 13	p.V424M	c.1270G > A	73405717	EC4	12/12, 44/45, 0/36	0	0	1	0/190	0	rs2305207	0.557	−0.572	Novel
	Exon 13	p.D428N	c.1282G > A	73405729	EC4	12/12, 39/45, 0/36	0	0	4**	0/190	0	rs188376296	0.103	−0.045	Novel
	Exon 35	p.I1406V	c.4216A > G	73498261	EC13	12/12, 43/44, 40/40.	0	0	1	1/189	0	rs192459984	0.029	−0.304	Novel
	Exon 38	p.G1583S	c.4747G > A	73501580	EC15	12/12, 44/44, 41/43	0	0	1	0/192	0	None	1.000	−4.967	Novel
	Exon 40	p.V1711I	c.5131G > A	73538009	EC16	12/12, 29/45, 11/41	0	0	1	1/192	1/12645	rs181611778	0.998	−0.599	Known	[12]
	Exon 42	p.G1799W	c.5395G > T	73544070	EC17	11/11, 45/45, 42/43	0	0	1**	0/192	0	None	0.998	−6.237	Novel
	Exon 44	p.V1908I	c.5722G > A	73545397	EC9	11/12, 28/45, 33/41	0	0	1	0/192	0	None	0.005	0.125	Known	[14]
	Exon 48	p.D2202E	c.6606C > A	73553291	EC21	12/12, 45/45, 41/42	0	0	1**	0/190	0	None	1.000	−3.068	Known	[28]
	Exon 48	p.Q2227P	c.6680A > C	73553365	EC21	12/12, 44/44, 23/41	0	0	1	0/192	0	None	0.729	−0.775	Known	[29]
	Exon 57	p.D2717N	c.8149G > A	73566009	EC25	12/12, 45/45, 42/42	0	0	1**	0/190	0	None	0.999	−1.909	Novel
	Exon 61	p.G2912S	c.8734G > A	73569588	EC27	11/11, 45/45, 42/42	0	0	1	0/192	0	None	0.774	−2.221	Known	[14]
	Exon 70	p.V3343M	c.10027G > A	73574997	-	12/12, 45/45, 16/37	0	0	1**	0/188	0	None	0.670	−0.427	Novel
Putative splice site	IVS2	-	c.68-3C > T	73206072	-	12/12, 40/44, 18/19	0	0	1	0/188	0	rs142456469	-	-	Novel
	IVS7	-	c.625-5C > T	73330542	-	11/12, 41/44, 0/40	0	0	1	0/192	0	None	-	-	Novel
	IVS52	-	c.7362 + 10G > A	73559396	-	12/12, 11/42, 5/20	0	0	1	0/192	0	None	-	-	Novel

*Evolutionary conservation showed up to 12 primates, 45 mammals, and 43 vertebrates, respectively.

**Combination of uncertain pathogenicity variants were counted as heterozygotes, not as compound heterozygotes.

Overlapping audiograms of all 21 subjects with biallelic CDH23 mutations are shown in Figure 2. The ages of these patients ranged from 0 to 25 years (median: 5 years). The average hearing level was 90.1 ± 12.3 (SD) dB. The average hearing level at 250 and 500 Hz was 70.5 ± 22.7 dB, whereas that at 2000 and 4000 Hz was 101.9 ± 7.8 dB. In addition, 10 of 21 subjects displayed obvious progressive hearing loss, as assessed by comparing audiograms obtained at younger ages. At the time of this study, no subjects were diagnosed with Usher syndrome, which, in addition to hearing loss, is associated with vestibular dysfunction and visual impairment due to retinitis pigmentosa. Information for vision, fundoscopy, and motor milestones in 21 subjects with biallelic CDH23 mutations is shown in Table 2.

Figure 2.

Overlapping audiograms of subjects with hearing loss caused by CDH23 mutations. Overlapping audiograms of the better-hearing ear of 20 subjects with homozygous or compound heterozygous CDH23 mutations.

Table 2.

Clinical and genetic data in the patients with biallelic CDH23 mutations

Case ID* 1	Age at the latestexamination	Genotypes* 2	Vision	Fundoscopy	Motor milestones* 3
1	25y11m	p.P240L / p.P240L	Normal	Not done	Normal
2	25y7m	p.P240L / p.P240L	Normal	Not done	Normal
3	25y2m	p.P240L / p.P240L	Normal	Not done	Normal
4	24y2m	p.P240L / p.P240L	Normal	Not done	Normal
5	17y3m	p.P240L / p.R2029W	Normal	Normal	Normal
6	14y1m	p.E2438K / p.N3044Tfs	Normal	Not done	Normal
7	13y3m	p.P240L / p.R2029W	Myopia	Normal	Normal
8	13y2m	p.D1626A / p.L2223Wfs	Normal	Not done	Normal
9	13y1m	p.P240L / p.P240L	Normal	Not done	Normal
10	11y8m	p.P240L / p.P240L	Normal	Not done	Normal
11	11y4m	p.E2438K / p.N3044Tfs	Normal	Not done	Normal
12	11y2m	p.D645G / p.E956K	Normal	Not done	Normal
13	9y7m	p.P240L / p.E956K	Myopia	Normal	Normal
14	9y2m	p.Q1716P / p.E2438K	Normal	Not done	Normal
15	8y5m	p.P240L / p.E956K	Normal	Not done	Normal
16	7y3m	p.P240L / p.E956K	Normal	Not done	Normal
17	7y0m	p.P240L / p.P240L	Normal	Not done	Normal
18	6y4m	p.P346S / p.Q1716P	Normal	Not done	Normal
20	5y9m	p.P240L / c.6712 + 1G > A	Normal	Not done	Normal
21	3y10m	p.P240L / c.6712 + 1G > A	Hyperopia	Normal	Normal

*¹Cases were shown in the order of their ages at the latest examination.

*²Genotypes written by bold word indicate truncating mutations.

*³Motor milestones: Head control < 4 months, Walking alone < 14 months.

The most frequent mutation in this study was p.P240L, which is consistent with previous reports of the Japanese population [12,14]. The overlapping audiograms illustrated that a high proportion of subjects homozygous for the p.P240L mutation had more severe low frequency hearing loss compared with subjects with non-p.P240L homozygous mutations, indicating a genotype-phenotype correlation (Figure 3).

Figure 3.

Comparison of hearing levels between individuals homozygous for p.P240L and those with other homozygous mutations. A: Overlapping audiograms of subjects with homozygous p.P240L mutations. B: Overlapping audiograms of the subjects with non-p.P240L homozygous mutations. The subjects with homozygous p.P240L mutations tended to have more severe hearing loss at lower frequencies.

Five of 21 subjects with biallelic CDH23 mutations had an allele with a truncating mutation, such as a frameshift or splice-site mutation, in association with a missense mutation on the other allele. The other 16 subjects had biallelic missense mutations. The overlapping audiograms of these subjects revealed no significant differences between the subjects with truncating mutations associated with missense mutations and those with biallelic missense mutations (Figure 4). The average hearing level of the subjects with an allele featuring truncating mutations associated with missense mutations was 90.3 ± 17.2 dB, whereas that of patients with biallelic missense mutations was 90.0 ± 10.2 dB. Because the number of subjects with truncating mutations was small, this result needs to be confirmed in a future study.

Figure 4.

Comparison of hearing levels between patients with truncating and missense mutations and those with biallelic missense mutations. A: Overlapping audiogram of subjects with truncating and missense mutations. B: Overlapping audiograms of the subjects with biallelic missense mutations. The patterns of the audiograms were similar.

Discussion

The present results revealed an extremely high prevalence of CDH23 mutations among patients with congenital sporadic or recessively inherited high-frequency hearing loss. Among 72 probands presenting with our defined set of clinical features, 13 subjects (18.1%) exhibited homozygous or compound heterozygous CDH23 mutations. Previously, a large cohort study of a Japanese population (n = 1396) using two-step screening revealed that the frequency of biallelic CDH23 mutations was only 1.6% in patients with hearing loss [14]. The higher prevalence of CDH23 mutations in the present study can be explained by subject selection criteria; these criteria included common clinical features of patients with CDH23 mutations [12,14,16], in addition to excluding patients with GJB2 and mitochondrial m.1555A > G and m.3243A > G mutations. The present results indicate that CDH23 mutations should be considered as candidate causes of hearing loss when patients present with clinical features similar to the selection criteria used in this study, which are relatively common among individuals with early childhood hearing loss.

A strategy for clinical genetic diagnosis should consider sensitivity, specificity, and cost. The specificity of Sanger sequencing is known to be extremely high, but the cost of analyzing CDH23 by Sanger sequencing is also extremely high. The present study revealed that its sensitivity for CHD23 was 18.1% at best. Considering these data and recent advances in genetic technologies, Sanger sequencing of CDH23 is not likely to be the most practical clinical test currently available. Recently, we and others have developed genetic tests using next-generation sequencing (NGS) for non-syndromic hearing loss [31-34]. The NGS-based tests can examine almost all known deafness genes simultaneously at a cost similar to that for Sanger sequencing of CDH23 [35,36]. Currently, clinical genetic testing using NGS is available in a limited number of institutes, but these tests will become more widely available in the near future. Because the clinical features of CDH23 mutation, i.e., congenital sporadic or recessively inherited high-frequency hearing loss, are relatively common and associated with mutations in many deafness genes, genetic tests using NGS would be appropriate for patients presenting with these clinical features.

Progression is reported as an important clinical feature of hearing loss caused by CDH23 mutations [14,16]. In our study, progression of hearing level loss was only noted in 10 of 21 subjects who had biallelic mutations. In the 11 subjects who did not display obvious progressive hearing loss, most were less than 5 years old at the time of this study. In general, it is difficult to demonstrate the progression of hearing loss in early childhood; the observation times for younger patients are shorter and the evaluation is performed using different audiological tests depending on the developmental stages. The results, therefore, tend to be unstable compared with those for adults. We believe these difficulties in proving the progression of hearing loss in early childhood explain why the ratio of progressive hearing loss in the present study was lower than that reported previously [14,16], and the ratio of hearing loss progression may be higher in a follow-up study.

This study identified truncating mutations of CDH23 in combination with heterozygous missense alleles in a Japanese population of patients with non-syndromic deafness. In general, individuals with USH1D mostly carry a truncated CDH23 protein because of nonsense, frameshift, or splice-site mutations, whereas those with DFNB12 usually carry missense mutations [7,10,13]. However, USH1D caused by missense mutations has also been reported [37]. In addition, it has been reported that the DFNB12 allele is phenotypically dominant to an USH1D allele [29]. The onset of visual impairment caused by retinitis pigmentosa accompanied by USH1D generally occurs during adolescence [9]. In this study, the ages of patients with monoallelic truncating mutations were 3–14 years, and none of these patients had biallelic truncating mutations. Therefore, at present we cannot determine whether these patients have DNFB12 or USH1D, although all clinical data are compatible with DFNB12 but not with USH1D. However, the detection of a mild visual phenotype requires patients to be followed with ophthalmoscopy and at least one electroretinography. This will provide more precise genotype-phenotype correlations.

Conclusions

Our results revealed that CDH23 mutations are highly prevalent in patients with congenital high-frequency sporadic or recessively inherited hearing loss and that the mutation spectrum was diverse, indicating that patients with these clinical features would merit genetic analysis.

Additional files

Additional file 1: Table S1. ^{(20.2KB, xlsx)}

Sequencing primers used in this study.

Additional file 2: Table S2. ^{(45.3KB, xlsx)}

Non-pathological variants found in this study.